ImClone, Merck Reach Deal Over Erbitux

Law360 (July 20, 2006, 12:00 AM EDT) -- New York-based ImClone Systems Inc. and Germany-based Merck KGaA have agreed to amend a 1998 development and licensing agreement that covers the blockbuster cancer drug Erbitux and other epidermal growth factor receptor, or EGFR, targeted antibodies.

Under the terms of the deal, which was announced Thursday, ImClone gave Merck permission to sublicense certain intellectual property rights to Japanese drug maker Takeda Pharmaceutical Co.

Takeda and Merck had signed an alliance last September regarding the anti-EGFR antibody Matuzumab.

“These agreements will allow Merck and Takeda to move...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.